FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutics and medicine. Humified material is exposed to alkaline hydrolysis in the presence of oxygen. Liquid phase is separated, acidified, produced residue is separated and washed until pH value is neutral, dried. Produced product is extracted by ester of carbonic acid, fluid extract is removed, produced residue is extracted by alkanol, alkanol is removed. Produced dry residue is purified by re-subsidence from alkaline solution with application of aqueous solution of mineral acid to produce target product.
EFFECT: invention makes it possible to produce highly efficient and low-toxic agent.
15 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIANGIOGENIC DRUG | 2016 |
|
RU2634253C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| PYRIDINE DERIVATIVES AS INHIBITORS OF VASCULAR ENDOTHELIUM GROWTH FACTOR RECEPTORS 2 (VEGFR-2) AND PROTEIN TYROSINE KINASE | 2009 |
|
RU2522444C2 |
| PHARMACEUTICAL COMPOSITION BASED ON PEPTIDE REGULATING DISTURBANCES OF ANGIOGENESIS, AND WAY OF ITS APPLICATION | 2007 |
|
RU2363488C1 |
| ANTHRANILIC ACID AMIDES, METHOD FOR THEIR PREPARING AND THEIR USING, METHOD FOR TREATMENT OF NEOPLASM DISEASE AMD PHARMACEUTICAL DRUG POSSESSING INHIBITORY ACTIVITY WITH RESPECT TO TYROSINE KINASE VEGF RECEPTOR | 2002 |
|
RU2318811C2 |
| RECOMBINANT HYBRID POLYPEPTIDE, CAPABLE OF INHIBITING HUMAN ENDOTHELIAL CELL PROLIFERATION IN VITRO, AND METHOD FOR PRODUCTION THEREOF | 2011 |
|
RU2465283C1 |
| SULFONAMIDE-CONTAINING INDOLE COMPOUNDS | 2000 |
|
RU2208607C2 |
| METHOD TO OBTAIN ANTITUMOR PREPARATION | 2000 |
|
RU2182482C1 |
| LIPOSOMAL PREPARATIONS | 2013 |
|
RU2817350C2 |
| FUSED PROTEIN WITH EFFECT OF ANGIOGENESIS INHIBITOR | 2008 |
|
RU2372354C1 |
